Dr. Reddy’s Laboratories Limited (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada. This move is significant as it positions Dr. Reddy’s among the first companies to introduce this generic product in the Canadian market, which is a notable expansion for the company after receiving approval from Health Canada.Dr. Reddy’s has launched its generic Semaglutide Injection, indicated for the treatment of type 2 diabetes, shortly after receiving market authorization on April 28, 2026. This launch underscores the company’s commitment to enhancing patient access to affordable medications in Canada, a market where it aims to establish a strong foothold.Despite the positive news for Dr. Reddy’s, the broader market faced challenges, with major indices like the Nasdaq down 1.90% and the S&P 500 down 1.45%. This mixed market backdrop suggests that while Dr. Reddy’s is making strides in product offerings, it is navigating a generally bearish market environment.Technical AnalysisFrom a technical perspective, Dr. Reddy’s shares are currently trading 1.8% above the 20-day simple moving average (SMA) of $13.37, indicating a short-term bullish sentiment. However, the stock is 0.9% below the 100-day SMA of $13.74 and 2.3% below the 200-day SMA of $13.93, which suggests potential resistance at these levels.The Relative Strength Index (RSI) currently sits at 53.44, indicating a neutral momentum phase, suggesting that the stock is neither overbought nor oversold. This neutral reading implies that there may be room for further price movement in either direction, depending on market conditions and upcoming catalysts.Key Resistance: $14.50 — a nearby level where rebounds can stall. Key Support: $13.50 — a nearby level where buyers previously stepped in.Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries.Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables, which make up 25% of its North America sales. The recent launch of its generic Semaglutide Injection in Canada highlights its strategy to expand access to GLP-1 therapies, reinforcing its commitment to providing affordable healthcare solutions.Earnings & Analyst OutlookDr. Reddy’s Laboratories Limited is slated to provide its next financial update on July 22, 2026 (estimated).